FDA’s Ortho Panel To Consider Study Designs For Less Invasive Spinal Devices
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial design issues for non-fusion spinal stabilization implants are among topics likely to be discussed by FDA's Orthopedic and Rehabilitation Devices Panel Sept. 9 in Gaithersburg, Md
You may also be interested in...
Disc Dynamics spinal nucleus replacement
Firm announces Aug. 2 approval to commence a clinical study of its Dascor disc arthroplasty system. Dascor is a minimally invasive nucleus replacement device intended for patients with disc degeneration not yet severe enough to warrant total disc replacement. Data from the trial, scheduled to begin during the third quarter, will support a premarket approval application for the device. The firm received a CE mark for Dascor in July 2005. Disc Dynamics is vying with NuVasive (NeoDisc), Cryolife (BioDisc) and Raymedica (PDN-Solo) to market the first spinal nucleus replacement system in the U.S. (1"The Gray Sheet" Sept. 5, 2005, p. 5)...
Disc Dynamics spinal nucleus replacement
Firm announces Aug. 2 approval to commence a clinical study of its Dascor disc arthroplasty system. Dascor is a minimally invasive nucleus replacement device intended for patients with disc degeneration not yet severe enough to warrant total disc replacement. Data from the trial, scheduled to begin during the third quarter, will support a premarket approval application for the device. The firm received a CE mark for Dascor in July 2005. Disc Dynamics is vying with NuVasive (NeoDisc), Cryolife (BioDisc) and Raymedica (PDN-Solo) to market the first spinal nucleus replacement system in the U.S. (1"The Gray Sheet" Sept. 5, 2005, p. 5)...
People In Brief
FoxHollow loses CEO: President & CEO Robert Thomas resigns, effective Jan. 1. Thomas, who joined the SilverHawk plaque excision system manufacturer in 1998 and has been CEO since 2000, announced plans to retire Dec. 12. Founder and Chairman John Simpson steps in as interim CEO while the firm searches for a permanent replacement. The 44-year-old Thomas cited personal reasons for his departure, but some analysts question that explanation, according to reports in the Wall Street Journal. FoxHollow's stock has fallen sharply, closing Jan. 5 at $30.12, down 35% from $46.44 Dec. 9, the last trading day before the announcement...